Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enanta Pharmaceuticals has signed licensing contract with Novartis to develop, manufacture and commercialize EDP-239, a NS5A inhibitor candidate for HCV.
Subscribe to our email newsletter
As per the agreement, Novartis will pay an upfront payment of $34m to Enanta and is even eligible to receive up to $406m if certain clinical, regulatory, and commercial milestones are met.
On worldwide sales of products, and retains co-detail rights in the US, Enanta may receive tiered double-digit royalties.
Novartis is responsible for all costs associated with the development, manufacture and commercialization of EDP-239.
Under the agreement, Novartis will fund Enanta’s drug discovery efforts on certain additional compounds targeting NS5A.
Enanta president and CEO Jay Luly said EDP-239 is a potent ingredient in combination drug therapy and preclinical studies have demonstrated high potency against multiple genotypes of the virus.